TY - JOUR
T1 - Real-life use of remdesivir in hospitalized patients with COVID-19
AU - COVID19-researcher group
AU - Garcia-Vidal, Carolina
AU - Meira, Fernanda
AU - Cózar-Llistó, Alberto
AU - Dueñas, Gerard
AU - Puerta-Alcalde, Pedro
AU - Garcia-Pouton, Nicole
AU - Chumbita, Mariana
AU - Cardozo, Celia
AU - Hernandez-Meneses, Marta
AU - Alonso-Navarro, Rodrigo
AU - Rico, Verónica
AU - Agüero, Daiana
AU - Bodro, Marta
AU - Morata, Laura
AU - Jordan, Carlota
AU - Lopera, Carlos
AU - Ambrosioni, Juan
AU - Segui, Ferran
AU - Grafia, Nacho
AU - Castro, Pedro
AU - García, Felipe
AU - Mensa, Josep
AU - Martínez, José Antonio
AU - Sanjuan, Gemma
AU - Soriano, Alex
N1 - Publisher Copyright:
©The Author 2021. Published by Sociedad Española de Quimioterapia.
PY - 2021
Y1 - 2021
N2 - Objective. Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain. Methods. We performed a descriptive study of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020. Results. A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Medi-an age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively. Conclusion. In our real-life experience, the use of rem-desivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.
AB - Objective. Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain. Methods. We performed a descriptive study of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020. Results. A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Medi-an age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively. Conclusion. In our real-life experience, the use of rem-desivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.
KW - Antivirals
KW - COVID-19
KW - Outcome
KW - Remdesivir
UR - https://www.scopus.com/pages/publications/85103607328
U2 - 10.37201/REQ/018.2021
DO - 10.37201/REQ/018.2021
M3 - Article
C2 - 33675220
AN - SCOPUS:85103607328
SN - 0214-3429
VL - 34
SP - 136
EP - 140
JO - Revista Espanola de Quimioterapia
JF - Revista Espanola de Quimioterapia
IS - 2
ER -
